Bristol Myers Squibb is facing investment scrutiny as it utilizes a wholly owned subsidiary, while the acquisition of the AI startup Manus in Beijing is ordered to unwind.
2 reports, 2 independent
Updated May 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol Myers Squibb is facing investment scrutiny as it utilizes a wholly owned subsidiary, while the acquisition of the AI startup Manus in Beijing is ordered to unwind.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BMS investment scrutiny, cell therapy ties to Meta, and the forced unwind of an AI startup acquisition in Beijing.1 source
BMY stock lagged IHE ETF performance on 2025-09-04.1 source
Keep exploring
The entities involved
-
Manus
AI agent
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
Nothing else this week.
-
Meta
American technology company
Coverage
Newest first; wire copies grouped- 933thedrive.com
- BarchartHow Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks? Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on de